{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:39:36Z","timestamp":1787063976361,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1124\/dmd.110.032805","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T01:02:54Z","timestamp":1281488574000},"page":"2000-2006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["ATP-Binding Cassette B1 Transports Seliciclib (R-Roscovitine), a Cyclin-Dependent Kinase Inhibitor"],"prefix":"10.1016","volume":"38","author":[{"given":"Zsuzsanna","family":"Rajnai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"M\u00e9hn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erzs\u00e9bet","family":"Be\u00e9ry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Okyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rton","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor K.","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferenc","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"L\u00e9vi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Krajcsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.110.032805_bib1","first-page":"417","article-title":"Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C","volume":"1","author":"Allen","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.110.032805_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s11095-008-9738-5","article-title":"Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro","volume":"26","author":"An","year":"2009","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.110.032805_bib3","doi-asserted-by":"crossref","first-page":"31208","DOI":"10.1074\/jbc.M500806200","article-title":"Roscovitine targets, protein kinases and pyridoxal kinase","volume":"280","author":"Bach","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.110.032805_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11095-004-9016-0","article-title":"A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier","volume":"22","author":"Bachmeier","year":"2005","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.110.032805_bib5","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1021\/jo049051v","article-title":"Stereochemistry of C-6 nucleophilic displacements on 1,1-difluorocyclopropyldibenzosuberanyl substrates. An improved synthesis of multidrug resistance modulator LY335979 trihydrochloride","volume":"69","author":"Barnett","year":"2004","journal-title":"J Org Chem"},{"key":"10.1124\/dmd.110.032805_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","article-title":"A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days","volume":"96","author":"Benson","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.110.032805_bib7","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.4161\/cc.8.9.8323","volume":"8","author":"Cappellini","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1124\/dmd.110.032805_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0169-409X(02)00175-8","article-title":"Considerations in the design and development of transport inhibitors as adjuncts to drug therapy","volume":"55","author":"Dantzig","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.110.032805_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","article-title":"Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine","volume":"243","author":"De Azevedo","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1124\/dmd.110.032805_bib10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.reprotox.2008.09.010","article-title":"The ontogeny of drug metabolizing enzymes and transporters in the rat","volume":"26","author":"de Zwart","year":"2008","journal-title":"Reprod Toxicol"},{"key":"10.1124\/dmd.110.032805_bib11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1124\/mol.107.034751","article-title":"Effect of breast cancer resistance protein (Bcrp\/Abcg2) on the disposition of phytoestrogens","volume":"72","author":"Enokizono","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.110.032805_bib12","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1182\/blood-2008-03-146704","article-title":"c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches","volume":"112","author":"Hallaert","year":"2008","journal-title":"Blood"},{"key":"10.1124\/dmd.110.032805_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2005.12.005","article-title":"Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats","volume":"69","author":"Hoffmann","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1124\/dmd.110.032805_bib14","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-08-1748","article-title":"Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer","volume":"15","author":"Hsieh","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.110.032805_bib15","doi-asserted-by":"crossref","first-page":"10720","DOI":"10.1158\/0008-5472.CAN-06-2086","article-title":"Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor","volume":"66","author":"Iurisci","year":"2006","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.110.032805_bib16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/ard.2007.086264","article-title":"Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance","volume":"68","author":"Kis","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/dmd.110.032805_bib17","series-title":"Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents","first-page":"187","article-title":"(R)-Roscovitine (CYC202, Seliciclib)","author":"Meijer","year":"2006"},{"key":"10.1124\/dmd.110.032805_bib18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.neuroscience.2004.07.051","article-title":"Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain","volume":"129","author":"Nies","year":"2004","journal-title":"Neuroscience"},{"key":"10.1124\/dmd.110.032805_bib19","series-title":"Trends in Cell Cycle Research","first-page":"293","article-title":"Circadian clock control of cell cycle pathways: relevance for cancer chronotherapeutics","author":"Okyar","year":"2008"},{"key":"10.1124\/dmd.110.032805_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.neuroscience.2008.06.015","article-title":"Subcellular localization of transporters along the rat blood-brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation","volume":"155","author":"Roberts","year":"2008","journal-title":"Neuroscience"},{"key":"10.1124\/dmd.110.032805_bib21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0026-895X(25)13623-7","article-title":"Reversal of resistance to adriamycin by 8-chloro-cyclic AMP in adriamycin-resistant HL-60 leukemia cells is associated with reduction of type I cyclic AMP-dependent protein kinase and cyclic AMP response element-binding protein DNA-binding activities","volume":"43","author":"Rohlff","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.110.032805_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.phrs.2008.05.010","article-title":"Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1\/2 in the rat brain","volume":"58","author":"Sallam","year":"2008","journal-title":"Pharmacol Res"},{"key":"10.1124\/dmd.110.032805_bib23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jps.21114","article-title":"Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane","volume":"97","author":"Shirasaka","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.110.032805_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2004.06.026","article-title":"Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells","volume":"6","author":"Szak\u00e1cs","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1124\/dmd.110.032805_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejps.2005.02.001","article-title":"Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat","volume":"25","author":"Vita","year":"2005","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.110.032805_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00210-008-0345-0","article-title":"A novel screening strategy to identify ABCB1 substrates and inhibitors","volume":"379","author":"von Richter","year":"2009","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/dmd.110.032805_bib27","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3324\/haematol.10680","article-title":"Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients\u2019 pretreatment status","volume":"92","author":"Weingrill","year":"2007","journal-title":"Haematologica"},{"key":"10.1124\/dmd.110.032805_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1172\/JCI8267","article-title":"Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier","volume":"105","author":"Wijnholds","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1124\/dmd.110.032805_bib29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.leukres.2008.10.011","article-title":"Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562\/MDR1","volume":"33","author":"Ye","year":"2009","journal-title":"Leuk Res"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624025327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624025327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.110.032805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:53:23Z","timestamp":1739879603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624025327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0090955624025327"],"URL":"https:\/\/doi.org\/10.1124\/dmd.110.032805","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATP-Binding Cassette B1 Transports Seliciclib (R-Roscovitine), a Cyclin-Dependent Kinase Inhibitor","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.110.032805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}